To include your compound in the COVID-19 Resource Center, submit it here.

EC approves AbbVie's HCV regimen

The European Commission approved Exviera dasabuvir and Viekirax, a two direct-acting-antiviral (2-DAA) combination of ombitasvir and paritaprevir plus the booster Norvir

Read the full 216 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE